Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability...
Hence then, the article about ascletis announces phase iii trial of denifanstat asc40 a first in class once daily oral fasn inhibitor for acne meets all endpoints was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints )
Also on site :
- Denver Fire Department responds to 3-alarm fire at intersection of Leetsdale Drive and S. Forest Street
- Trial to begin for police officer charged in delayed response to Uvalde school shooting
- China’s special envoy meets Maduro (VIDEO)